IPO registrations (S-1, F-1) · Underwriters
James Securities, Inc
- Deals
- 6 priced offerings as an underwriter, 2 as lead manager or representative; 4 initial public offerings
- Proceeds of those deals
- $92,728,366 ($48,412,091 as lead)
- Years
- 2015–2024
- Named in
- 16 prospectuses and registration statements in all, including offerings not yet priced or withdrawn
Deals by year
| Year | Deals | As lead | Proceeds of deals |
|---|---|---|---|
| 2024 | 1 | 1 | $6,612,091 |
| 2020 | 2 | 0 | $32,640,025 |
| 2019 | 1 | 0 | $4,356,250 |
| 2018 | 1 | 0 | $7,320,000 |
| 2015 | 1 | 1 | $41,800,000 |
Deals 6
| Priced | Company | Role | Price | Range | Shares | Proceeds | Listing | Kind | Syndicate | Prospectus |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-14 | Glucotrack, Inc. NJ | Lead | $1.39 | 4,756,900 | $6,612,091 | Nasdaq GCTK | Offering | 3 | 424B4 ↗ | |
| 2020-12-28 | INTELLIGENT BIO SOLUTIONS INC. NY | Syndicate | $17.00 | - | $21,600,013 | Nasdaq GBS | IPO | 5 | 424B4 ↗ | |
| 2020-07-01 | Aditxt, Inc. VA | Syndicate | $9.00 | 1,226,668 | $11,040,012 | Nasdaq ADTX | IPO | 5 | 424B4 ↗ | |
| 2019-02-13 | IMAC Holdings, Inc. TN | Syndicate | $5.12 | 850,000 | $4,356,250 | Nasdaq IMAC | IPO | 4 | 424B4 ↗ | |
| 2018-07-30 | Azora Therapeutics, Inc. (DE) CA | Syndicate | $5.00 | 1,464,000 | $7,320,000 | Nasdaq ADIL | IPO | 4 | 424B4 ↗ | |
| 2015-07-27 | Healthier Choices Management Corp. FL | Lead | $11.00 | - | $41,800,000 | Nasdaq VPCO | Offering | 3 | 424B4 ↗ |
“Offering” is a priced registered offering that the cover page does not describe as an initial public offering: a follow-on, a resale, or a small company’s best-efforts deal.
Registrations in progress or never priced 4
| Filed | Company | Role | Range | Shares | Listing | Status | Document |
|---|---|---|---|---|---|---|---|
| 2022-04-14 | Oxeia Biopharmaceuticals, Inc. | Syndicate | $6.00–$8.00 | - | Nasdaq OXEA | Withdrawn 2022-06-08 | S-1 ↗ |
| 2021-05-20 | NUGENEREX IMMUNO-ONCOLOGY, INC. | Syndicate | 5,555,556 | Nasdaq NGIO | Pending | S-1/A ↗ | |
| 2020-09-14 | GENEREX BIOTECHNOLOGY CORP | Syndicate | 1,000,000 | Nasdaq GNBTP | Withdrawn 2005-03-11 | S-1/A ↗ | |
| 2014-12-15 | Workhorse Group Inc. | Lead | - | OTC AMPD | Withdrawn 2015-01-16 | S-1 ↗ |
Works alongside
| Firm | Deals together | Of which that firm led |
|---|---|---|
| Dawson James | 6 | 3 |
| of Contents | 3 | 0 |
| The Benchmark Company | 2 | 0 |
| ViewTrade | 2 | 0 |
| Axiom Capital Management | 1 | 0 |
| Gunnar & Co | 1 | 0 |
| Joseph Gunnar | 1 | 1 |
| Securities, Inc | 1 | 0 |
| WestPark Capital, Inc | 1 | 0 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Offering terms are read from the cover pages of the registrant's final prospectus (424B4, 424B1) and its latest registration statement before pricing: the price range, the final price, shares offered, gross proceeds (the cover's total, else price times shares), exchange and ticker, and the underwriters named on the cover and in the underwriting table (loader/s1_terms.py). Underwriter names are normalised, so Goldman, Sachs & Co. of 1999 and Goldman Sachs & Co. LLC of 2024 are one firm.